Search PubMed⌕ Search

Biomedical subjects

M Olsen

Publications and source records attributed to M Olsen.

At least 73 records · Page 4Linked to original sources
PubMed1989

Sucralfate as maintenance treatment for the prevention of duodenal ulcer recurrence.

Eighty-eight patients with endoscopically proven and healed duodenal or pyloric ulcer were randomly allocated into a double-blind, placebo-controlled, 12-month maintenance trial to determine whether sucralfate, 1 g twice daily, can be used to prevent a recurrence of ulceration. The patients were assessed endoscopically at three, six, and 12 months, or earlier if a symptomatic relapse occurred. Serum aluminum levels were also monitored. Sixteen patients were excluded from the study during the follow-up: nine of 41 in the sucralfate group, and seven of 47 in the placebo group. The groups did not differ with respect to age, sex, or smoking. The cumulative relapse rates in the sucralfate group were 28 percent after three months, 33 percent after six months, and 45 percent after 12 months, as compared with 49 percent (p less than 0.05), 64 percent (p less than 0.01), and 68 percent (p less than 0.05), respectively, in the placebo group. It is concluded that 1 g sucralfate twice daily is more effective than a placebo and is safe for the maintenance treatment of duodenal and pyloric ulcer disease.

Adult↗
PubMed1988

Trainability of the pelvic floor. A prospective study during pregnancy and after delivery.

The contractibility and trainability of the pelvic floor were investigated during pregnancy and after vaginal delivery in 86 healthy primiparae. One group (TG) (n = 38) was instructed in training the pelvic floor from the 33rd week of pregnancy, whereas the other group (non-TG) (n = 39) was not. Both groups were measured by perineometry five times between 33rd-39th week of pregnancy and approximately 8 weeks after delivery. Half of the women were also measured 8 months post partum. At the beginning of the study both groups showed the same strength of the pelvic floor. 8 weeks and 8 months after delivery the TG were significantly (p less than 0.05) better able to contract the pelvic floor compared with the non-TG. 8 months post partum, the TG had regained the initial values of pelvic floor contraction as from 33rd week of pregnancy, whereas the non-TG had not. During pregnancy there was a better ability to contract the pelvic floor in the TG vis-à-vis the non-TG, though not significantly so. No difference in the course of delivery was observed, and the frequency of complications was the same in the two groups.

Adolescent↗
PubMed1987

Sucralfate versus placebo in treatment of non-ulcer dyspepsia.

One hundred fifty-one patients with non-ulcer dyspepsia, defined as chronic epigastric pain without concomitant symptoms of the irritable bowel syndrome and with no evidence of any organic disease other than macroscopic or microscopic gastritis/duodenitis seen at endoscopy on entry into the trial, were randomly assigned to treatment for four weeks with sucralfate or a placebo, 1 g three times a day one-half hour before meals, according to a double-blind model. Seventy-nine patients received sucralfate and 72 patients received a placebo. According to patients' subjective assessment of their symptoms at four weeks, 61 patients (77 percent) in the sucralfate group and 40 patients (56 percent) in the placebo group had become symptom-free or showed improvement, whereas the condition of 18 (23 percent) in the former group compared with 32 (44 percent) in the latter group remained unchanged or deteriorated. The difference between the groups was significant (p less than 0.01). The best response to sucralfate treatment (84 percent or more symptom-free or improved) was achieved in patients with mild or moderate symptoms and without macroscopic or microscopic inflammation of their gastric mucosa--a typical patient with non-ulcer dyspepsia. Our results indicate that sucralfate is significantly more effective than placebo in the treatment of non-ulcer dyspepsia.

Adult↗
PubMed1987

Metabolism of zearalenone by sow intestinal mucosa in vitro.

Homogenized intestinal mucosa samples from sows were incubated with zearalenone in the presence of NADPH or UDPGA. In addition, UDPglucuronosyltransferase activity in the microsomal fraction of mucosa was determined using 1-naphthol as substrate. In the presence of NADPH, zearalenone was reduced to both alpha- and beta-zearalenol (0.37 +/- 0.18 and 0.29 +/- 0.11 nmol/mg protein/hr in the duodenum and jejunum, respectively). The beta-isomer was the predominant metabolite. Glucuronide conjugation of zearalenone was very high compared with the level of reduction occurring (11.3 +/- 6.1 and 9.4 +/- 5.8 nmol conjugated/mg protein/hr in the duodenum and jejunum, respectively). There was no correlation between the rates of glucuronide conjugation of zearalenone and 1-naphthol, indicating that they depend upon two different isoenzymes of UDPglucuronosyltransferase.

Animals↗
PubMed1987

Epitope mapping of monoclonal antibodies to gag protein p19 of avian sarcoma and leukaemia viruses.

We have characterized a set of 15 monoclonal antibodies to p19gag, one of the internal proteins of avian sarcoma and leukaemia viruses. All the antibodies work in immune precipitations as well as in immunoblotting, though with different efficiencies. We have developed a simple epitope mapping technique, which uses partial chemical cleavages at methionine or tryptophan residues followed by immunoblotting from SDS-polyacrylamide gels, to localize the epitopes of nine of these antibodies. The epitopes fall into at least four classes. The mapping procedure should also be useful for other antigens of known primary structure.

Antibodies, Monoclonal↗
PubMed1986

Metabolism of high concentrations of dietary zearalenone by young male turkey poults.

Six male turkey poults (3 weeks of age) were fed a starter ration artificially contaminated with 800 mg zearalenone/kg for a 2-week period to examine zearalenone metabolism and residues in various tissues, excreta, and blood plasma. Zearalenone had no effect on either feed consumption or body weight gain. All the birds fed zearalenone frequently showed strutting behavior, displayed an increased size and coloration of caruncles and dewlaps, and had swollen vent tissue. None of these signs were seen among six control birds fed uncontaminated starter feed. Hormone analysis, however, revealed that the testosterone concentrations in blood plasma were the same in both controls and treated birds. Analysis after 14 days of feeding showed that most of the dietary zearalenone had been metabolized into alpha-zearalenol. Levels of zearalenone and alpha-zearalenol were: blood plasma 66 +/- 27 and 194 +/- 80 ng/ml, excreta 182 +/- 33 and 644 +/- 86 micrograms/g, lung 56 +/- 45 and 202 +/- 161 ng/g, heart 57 +/- 40 and 238 +/- 121 ng/g, kidney 122 +/- 25 and 477 +/- 53 ng/g, and liver 276 +/- 54 and 2715 +/- 590 ng/g, respectively. Only traces of beta-zearalenol could be detected in plasma, excreta, and the various tissues. The percentage alpha-zearalenol of total zearalenone plus alpha-zearalenol rose significantly in both blood plasma and excreta during the experimental period. Almost all zearalenone and alpha-zearalenol was found conjugated in blood plasma, and the conjugates consisted of both glucuronides and sulfate conjugates. Approximately 65% of all zearalenone and alpha-zearalenol in excreta was found to be conjugated.

Animals↗
PubMed1985

Plasma and urinary levels of zearalenone and alpha-zearalenol in a prepubertal gilt fed zearalenone.

One prepubertal gilt, fed 192 micrograms zearalenone/kg body weight/day for 4 days, showed plasma concentrations of alpha-zearalenol 3-4 times higher than of the parent compound during the treatment. Zearalenone and alpha-zearalenol could be traced in plasma until the 5th day and in urine until the 4th day of the posttreatment period. A maximum circulating amount of zearalenone plus alpha-zearalenol, 10.4 ng/ml plasma, was found on the 4th day of treatment followed by an urinary excretion of 305 ng/ml urine. All zearalenone and alpha-zearalenol in plasma and urine were bound to glucuronic acid. On the second day of treatment the animal showed oedema and reddening of the vulva which became more pronounced during the treatment. Hormone analysis, however, showed that the animal had no oestrus cycle during the 3 week experimental period.

Animals↗
PubMed1984

Metabolism of aflatoxin, ochratoxin, zearalenone, and three trichothecenes by intact rumen fluid, rumen protozoa, and rumen bacteria.

The effect of rumen microbes on six mycotoxins (aflatoxin B1, ochratoxin A, zearalenone, T-2 toxin, diacetoxyscirpenol, and deoxynivalenol ) considered to be health risks for domestic animals was investigated. The mycotoxins were incubated with intact rumen fluid or fractions of rumen protozoa and bacteria from sheep and cattle in the presence or absence of milled feed. Rumen fluid had no effect on aflatoxin B1 and deoxynivalenol . The remaining four mycotoxins were all metabolized, and protozoa were more active than bacteria. Metabolism of ochratoxin A, zearalenone, and diacetoxyscirpenol was moderately or slightly inhibited by addition of milled feed in vitro. The capacity of rumen fluid to degrade ochratoxin A decreased after feeding, but this activity was gradually restored by the next feeding time. Ochratoxin A was cleaved to ochratoxin alpha and phenylalanine; zearalenone was reduced to alpha-zearalenol and to a lesser degree to beta-zearalenol; diacetoxyscirpenol and T-2 toxin were deacetylated to monoacetoxyscirpenol and HT-2 toxin, respectively. Feeding of 5 ppm (5 mg/kg) of ochratoxin A to sheep revealed 14 ppb (14 ng/ml) of ochratoxin A and ochratoxin alpha in rumen fluid after 1 h, but neither was detected in the blood. Whether such conversions in the rumen fluid may be considered as a first line of defense against toxic compounds present in the diet is briefly discussed.

Aflatoxin B1↗
PubMed1983

Species differences in zearalenone-reducing activity in subcellular fractions of liver from female domestic animals.

The subcellular distribution of the zearalenone-reducing activity in liver from female pig, goat, sheep, cow and hen was investigated. The distribution patterns for the reduction of zearalenone to alpha- or beta-zearalenol differed between species and was also dependent upon coenzyme. Pig and goat had the greatest ability to form both alpha- and beta-zearalenol in the microsomal fraction independently of coenzyme. Cow and hen formed alpha-zearalenol almost entirely in the microsomal fraction and beta-zearalenol only in the cytosol fraction and only with NADPH as coenzyme. The sheep was distinct from the pig and goat in having the highest alpha-zearalenol forming activity in the cytosol fraction when NADPH was used as coenzyme.

Animals↗
PubMed1981

Reduction of zearalenone to zearalenol in female rat liver by 3 alpha-hydroxysteroid dehydrogenase.

The distribution of the zearalenone reducing activity was investigated in liver fractions obtained by differential centrifugation of liver homogenate from adult female Sprague Dawley rats. The zearalenone reducing enzyme was identified as 3 alpha-hydroxysteroid dehydrogenase. At least two multiple forms occur of the enzyme with different subcellular locations and pH-optima. The activity was localized in the microsomes with NADH as coenzyme and in both microsomes and cytosol with NADPH.

3-Hydroxysteroid Dehydrogenases↗
PubMed1978

Effects of cold stress on rats fed different levels of docosenoic acids.

Male Sprague-Dawley rats, 4 weeks old, were subjected to an ambient temperature of 4 C for periods up to 24 days and fed a synthetic diet containing one of the following oils: peanut oil (PO), rapeseed oil (RO), low erucic acid rapeseed oil (LO), and partially hydrogenated marine oil (HO), each at 20% w/w. A parallel experiment using the same oils was performed at room temperature (23 C). During cold stress, animals on the RO diet showed higher mortality than all other groups; all 20 animals in this group died within 5 days. At room temperature, however, all animals survived. The lipid accumulation in the heart reached its peak in all groups after 3 days and then gradually declined. The accumulation was most pronounced in the RO animals and coincided with the high mortality at 4 C. The fatty acid composition of the cardiac triglycerides reflected that of the diet, while the composition of the cardiac lecithin was only marginally modified.

Animals↗